Abiopharma

Presentation for the capital market - H1-2026

Amended report for a dividend in the amount of 0.61130 dollars per share, ex date: 4.9.26, payment 15.9.26 - update of dividend amount

Reminder regarding an investors’ conference to be held on 27.8.26 at 18:30

Dividend in the amount of 61.13031 agorot per share, ex date: 4.9.26, payment 15.9.26

The company’s liability position as of June 30, 2026, by maturity dates

Letter from the CEO to the shareholders

Q2/semi-annual report for 2026

Extension of the exercise period of non-tradable warrants allocated in a private placement dated 23.2.26

Approval of a purchase plan

Receipt of an order of approximately $1.3 million from a customer in Europe, to be supplied in Q2 2027